Three molecular determinants of malignant conversion and their potential as therapeutic targets

Current Opinion in Oncology

Volumn 11, Issue 1, 1999, Pages 58-67

  Dome, Jeffrey S ^a   Look, A Thomas ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

ENZYME ACTIVATION; GENE MUTATION; HOMEOSTASIS; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

CELL AGING; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; MODELS, GENETIC; MUTATION; NEOPLASMS; PROTEINS; TELOMERASE; TRANS-ACTIVATORS;

EID: 0033036239     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199901000-00013     Document Type: Review

References (112)

1. 1 Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
2. 2 Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC: Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990, 346:866-868.
3. 3 Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, et al: Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 1992, 89:10114-10118.
4. 4 Harley CB: Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991, 256:271-282.
5. 5 Holt SE, Shay JW, Wright WE: Refining the telomere-telomerase hypothesis of aging and cancer. Nature Biotechnology 1996, 14:836-839.
6. 6 Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
7. 7 Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddie SD, et al: hEST2, the putative human telomerase catalytic subunit gene, is upregulated in tumor cells and during immortalization. Cell 1997, 90:785-795. Appearing contemporaneously with the study of Nakamura et al. (Science 1997, 277:955-959), this article identified the human gene encoding the catalytic subunit of telomerase and named it hEST2. Expression of this gene, which was mapped to chromosome 5p15.33, was noted at high levels in primary tumors, cell lines, and telomerase-positive tissues but was undetectable in telomerase-negative cells and tissues. The Human Genome Organization Nomenclature Committee renamed this gene hTERT.
8. 8 Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al: Telomerase catalytic subunit homologs from fission yeast and human. Science 1997, 277:955-959. This article reports the cloning of the human gene that encodes the catalytic subunit of telomerase. Named hTRT, this gene was identified on the basis of its homology to telomerase-encoding genes in Saccharomyces cerevisiae and Euplotes aediculatus. Sequence comparisons placed the telomerase proteins in the reverse transcriptase family. Expression of hTRT correlated with the presence of telomerase activity in cell lines, suggesting that telomerase activity is regulated, in part, by the transcription or stabilization of nTRT mRNA.
9. 9 Counter CM, Meyerson M, Eaton EN, Weinberg RA: The catalytic subunit of yeast telomerase. Proc Natl Acad Sci U S A 1997, 94:9202-9207. The product of the EST2 gene was identified as a subunit of telomerase in the yeast S. cerevisiae. Immunochemical experiments showed that the EST2 protein is an integral subunit of the telomerase enzyme complex. Mutations in EST2 resulted in the absence of telomerase activity, suggesting a direct catalytic role for the EST2 protein.
10. 10 Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR: Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 1997, 276:561-567.
11. 11 Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RA: Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998, 16:1217-1222. When an epitope-tagged version of hTERT was ectopically expressed in telomerase-negative cells, telomerase activity was induced with levels comparable to those seen in immortal telomerase-positive cells. The authors concluded that the synthesis of hTERT protein subunits represents the rate-limiting determinant of cellular telomerase activity.
12. 12 Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, et al.: Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998, 18:65-68. Telomerase-negative normal fibroblasts were transfected with vectors encoding wild-type and mutant forms of hTERT. Expression of wild-type hTERT resulted in detectable telomerase activity, whereas expression of hTERT mutants did not. Hepatocellular carcinoma and noncancerous liver tissues were evaluated for telomerase activity and hTERT, hTR, and TP1 expression. Only hTERT correlated with telomerase activity, suggesting that expression or stabilization of hTERT transcripts plays a key role in the regulation of telomerase.
13. 13 Beattie TL, Zhou W, Robinson MO, Harrington L: Reconstitution of human telomerase activity in vitro. Curr Biol 1998, 8:177-180.
14. 14 Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, et al.: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997, 17:498-502. In vitro transcription and translation of hTERT, when cosynthesized with hTR, reconstituted telomerase activity that exhibited enzymatic properties resembling those of the native enzyme. Mutations in the reverse transcriptase motifs reduced or abolished enzymatic activity. Normal human fibroblasts transiently expressing hTERT turned on telomerase, suggesting that hTERT is the limiting component necessary for the activation of this enzyme.
15. 15 Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al.: Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279:349-352. Two telomerase-negative human cell types, retinal pigment epithelial cells and foreskin fibroblasts, were transfected with vectors encoding hTERT. In contrast to telomerase-negative control cells, which exhibited telomere shortening and senescence, telomerase-expressing cells had elongated telomeres and divided vigorously without genetic instability for more than 20 doublings beyond their expected life span. This experiment establishes a causal relationship between telomere shortening and in vitro cellular senescence.
16. 16 Vaziri H, Benchimol S: Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998, 8:279-282.
17. 17 Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al.: The RNA component of human telomerase. Science 1995, 269:1236-1241.
18. -/- mice indicate an essential role for telomerase in the long-term viability of organ systems with self-renewing capability.
19. -/- mice lacked detectable telomerase activity, yet were viable for the six generations analyzed. Telomeres shortened over time and were completely eroded by the fourth generation, resulting in aneuploidy and other chromosomal abnormalities. Telomerase-deficient cells could be immortalized in culture, could be transformed by viral oncogenes, and were able to generate tumors in nude mice. The authors conclude that although telomerase is necessary for telomere maintenance, it is not required for oncogenic transformation or tumor formation in mice. These findings might not apply to human malignant transformation; because mouse telomeres are significantly longer than human telomeres, humans may require the activation of telomerase at an earlier stage in the multi-step process of tumorigenesis.
20. 20. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR: Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997, 3:1271-1274. The vast majority of human tumor-derived cell lines exhibit telomerase activity. In this study, 4 of 47 human tumor-derived cell lines lacked telomerase activity but possessed long telomeres. The terminal restriction fragment pattern of these cells differed from that of telomerase-positive cells, suggesting that an alternative mechanism of telomere lengthening (ALT) occurs. Additionally, 4 of 57 tissue samples, representing a variety of human tumor types, had abnormally long telomeres in the face of telomerase negativity. Of the eight tumor samples and cell lines displaying ALT, four were from osteosarcoma. The authors suggest that telomerase is more stringently regulated in nonepithelial cells, which selects for ALT activation as a telomere-lengthening mechanism. The presence of ALT has implications regarding the therapeutic uses of telomerase inhibitors.
21. 21 Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Program A, et al.: A mammalian telomerase-associated protein. Science 1997, 275:973-977.
22. 22 Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M: Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 1998, 58:1558-1561.
23. 23 Sharma HW, Sokoloski JA, Perez JR, Maltese JY, Sartorelli AC, Stein CA, et al.: Differentiation of immortal cells inhibits telomerase activity. Proc Natl Acad Sci U S A 1995, 92:12343-12346.
24. 24 Holt SE, Wright WE, Shay JW: Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 1996, 16:2932-2939.
25. 25 Bestilny LJ, Brown CB, Miura Y, Robertson LD, Riabowol KT: Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. Cancer Res 1996, 56:3796-3802.
26. 26 Fujimoto K, Takahashi M: Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA. Biochem Biophys Res Commun 1997, 241:775-781.
27. 27 Ku WC, Cheng AJ, Wang TC: Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem Biophys Res Commun 1997, 241:730-736.
28. 28 Xu HJ, Zhou Y, Ji W, Perng GS, Kruzelock R, Kong CT, et al.: Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 1997, 15:2589-2596.
29. 29 Clark GM, Osborne CK, Levitt D, Wu F, Kim NW: Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst 1997, 89:1874-1881.
30. 30 Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, et al.: High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 1997, 89:1609-1615.
31. 31 Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, et al.: Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995, 155:3711-3715.
32. 32 Buchkovich KJ, Greider CW: Telomerase regulation during entry into the cell cycle in normal human T cells. Mol Biol Cell 1996, 7:1443-1454.
33. 33 Harle-Bachor C, Boukamp P: Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci U S A 1996, 93:6476-6481.
34. 34 Weng NP, Granger L, Hodes RJ. Telomere lengthening and telomerase activation during human B cell differentiation. Proc Natl Acad Sci U S A 1997, 94:10827-10832.
35. 35 Kyo S, Takakura M, Tanaka M, Kanaya T, Inoue M: Telomerase activity in cervical cancer is quantitatively distinct from that in its precursor lesions. Int J Cancer 1998, 79:66-70.
36. 36 Greider CW: Telomerase activity, cell proliferation, and cancer. Proc Natl Acad Sci U S A 1998, 95:90-92.
37. 37 Belair CD, Yeager TR, Lopez PM, Reznikoff CA: Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci U S A 1997, 94:13677-13682. A point of controversy is whether telomerase activity is indicative of malignant transformation or is simpiy a marker of active proliferation. In this study, biopsies were performed on normal human uroepithelial cells, and these cells were found to lack telomerase activity. When the same cells were established as proliferating cultures, however, telomerase activity was readily detected. In nonproliferating human uroepithelial cell cultures, telomerase activity was low or undetectable. The authors conclude that proliferative index accounts for the differences between telomerase activity in normal and tumor cells.
38. 38 Zhang W, Kapusta LR, Slingerland JM, Klotz LH: Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res 1998, 58:619-621.
39. 39 Coursen JD, Bennett WP, Gollahon L, Shay JW, Harris CC: Genomic instability and telomerase activity in human bronchial epithelial cells during immortalization by human papillomavirus-16 E6 and E7 genes. Exp Cell Res 1997, 235:245-253.
40. 40 van Steensel B, de Lange T: Control of telomere length by the human telomeric protein TRF-1. Nature 1997, 385:740-743.
41. 41 Cooper JP, Nimmo ER, Allshire RC, Cech TR: Regulation of telomere length and function by a Myb-domain protein in fission yeast. Nature 1997, 385:744-747.
42. 42 Broccoli D, Smogorzewska A, Chong L, de Lange T: Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat Genet 1997, 17:231-235.
43. 43 Bilaud T, Brun C, Ancelin K, Koering CE, Laroche T, Gilson E: Telomeric localization of TRF-2, a novel human telobox protein. Nat Genet 1997, 17:236-239.
44. 44 Umbricht CB, Saji M, Westra WH, Udelsman R, Zeiger MA, Sukumar S: Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. Cancer Res 1997, 57:2144-2147.
45. 45 Shroyer KR, Thompson LC, Enomoto T, Eskens JL, Shroyer AL, McGregor JA: Telomerase expression in normal epithelium, reactive atypia, squamous dysplasia, and squamous cell carcinoma of the uterine cervix. Am J Clin Pathol 1998, 109:153-162.
46. 46 Iwasaka T, Zheng PS, Yokoyama M, Fukuda K, Nakao Y, Sugimori H: Telomerase activation in cervical neoplasia. Obstet Gynecol 1998, 91:260-262.
47. 47 Carey LA, Hedican CA, Henderson GS, Umbricht CB, Dome JS, Varon D, Sukumar S: Careful histological confirmation and microdissection reveal telomerase activity in otherwise telomerase-negative breast cancers. Clin Cancer Res 1998, 4:435-440.
48. 48 Poremba C, Bocker W, Willenbring H, Schafer KL, Potterbach F, Burger H, et al.: Telomerase activity in human proliferative breast lesions. Int J Oncol 1998, 12:641-648.
49. 49 Villa R, Zaffaroni N, Folini M, Martelli G, De Palo G, Daidone MG, Silvestrini R: Telomerase activity in benign and malignant breast lesions: a pilot prospective study on fine-needle aspirates. J Natl Cancer Inst 1998, 90:537-539.
50. 50 Saji M, Westra WH, Chen H, Umbricht CB, Tuttle RM, Box MF, et al.: Telomerase activity in the differential diagnosis of papillary carcinoma of the thyroid. Surgery 1997, 122:1137-1140.
51. 51 Kavaler E, Landman J, Chang Y, Droller MJ, Liu BC: Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998, 82:708-714.
52. 52 Duggan BD, Wan M, Yu MC, Roman LD, Muderspach LI, Delgadillo E, et al.: Detection of ovarian cancer cells: comparison of a telomerase assay and cytologic examination. J Natl Cancer Inst 1998, 90:238-242.
53. 53 Yang CT, Lee MH, Lan RS, Chen JK: Telomerase activity in pleural effusions: diagnostic significance. J Clin Oncol 1998, 16:567-573.
54. 54 Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW: Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995, 1:249-255.
55. 55 Hiyama E, Yokoyama T, Tatsumoto N, Hiyama K, Imamura Y, Murakami Y, et al.: Telomerase activity in gastric cancer. Cancer Res 1995, 55:3258-3262.
56. 56 Okusa YSN, Ichikura T, Mochizuki H: Correlation between telomerase activity and DNA ploidy in gastric cancer. Oncology 1998, 55:258-264.
57. 57 Suda T, Isokawa O, Aoyagi Y, Nomoto M, Tsukada K, Shimizu T, et al.: Quantitation of telomerase activity in hepatocellular carcinoma: a possible aid for a prediction of recurrent diseases in the remnant liver. Hepatology 1998, 27:402-406.
58. 58 Hoos A, Hepp HH, Kaul S, Ahlert T, Bastert G, Wallwiener D: Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. Int J Cancer 1998, 79:8-12.
59. 59 Ahn MJ, Noh YH, Lee YS, Lee JH, Chung TJ, Kim IS, et al.: Telomerase activity and its clinicopathological significance in gastric cancer. Eur J Cancer 1997, 33:1309-1313.
60. 60 Kondo Y, Kondo S, Tanaka Y, Haqqi T, Barna BP, Cowell JK: Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 1998, 16:2243-2248. Because telomerase is essential for stabilizing DNA, this study tested the hypothesis that inhibition of telomerase would render cells more sensitive to DNA-damaging agents. Telomerase-positive cells from a human glioblastoma cell line were transfected with an antisense vector for hTR, the RNA template of telomerase. This action resulted in inhibition of telomerase and increased susceptibility to apoptotic cell death induced by the agent cisplatin. The authors suggest that inhibition of telomerase may represent a new chemosensitization technique for tumors resistant to anticancer therapy.
61. 61 Strahl C, Blackburn EH: The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena. Nucleic Acids Res 1994, 22:893-900.
62. 62 Strahl C, Blackburn EH: Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996, 16:53-65.
63. 63 Pai RB, Pai SB, Kukhanova M, Dutschman GE, Guo X, Cheng YC: Telomerase from human leukemia cells: properties and its interaction with deoxynucleoside analogues. Cancer Res 1998, 58:1909-1913.
64. 64 Kalderon D: Hedgehog signalling: Ci complex cuts and clasps. Curr Biol 1997, 7:R759-R762.
65. 65 Ingham PW: The patched gene in development and cancer. Curr Opin Genet Dev 1998, 8:88-94.
66. 66 Robbins DJ, Nybakken KE, Kobayashi R, Sisson JC, Bishop JM, Therond PP: Hedgehog elicits signal transduction by means of a large complex containing the kinesin-related protein costal2. Cell 1997, 90:225-234. Appearing concurrently with the work of Sisson et al. (Cell 1997, 90:235-245), this article demonstrates that costal2 (cos2), cubitus interruptus (ci), and fused (fu) associate in a large protein complex. In the absence of hedgehog (hh) signaling, the complex bound microtubules, but in its presence, the bindinq was reversed. The authors suggest that the cos2/ci/fu complex may mediate hh signaling by governing access of ci to the nucleus.
67. 67 Sisson JC, Ho KS, Suyama K, Scott MP: Costal2, a novel kinesin-related protein in the hedgehog signaling pathway. Cell 1997, 90:235-245. This article reports the molecular identity of the Drosophila costal2 (cos2) gene. The gene encodes a protein that is distantly related to the kinesin family of proteins that bind and move along microtubules. Cos2 accumulated preferentially in cells capable of responding to hedgehog (hh) and bound microtubules. Cos2 was found to associate with cubitus interruptus (ci) in large protein complexes, suggesting that cos2 could participate in the regulation of ci.
68. 68 Aza-Blanc P, Ramirez-Weber FA, Laget MP, Schwartz C, Kornberg TB: Proteolysis that is inhibited by hedgehog targets cubitus interruptus protein to the nucleus and converts it to a repressor. Cell 1997, 89:1043-1053.
69. 69 Chen Y, Gallaher N, Goodman RH, Smolik SM: Protein kinase A directly regulates the activity and proteolysis of cubitus interruptus. Proc Natl Acad Sci U S A 1998, 95:2349-2354. This study demonstrates that PKA-mediated phosphorylation of cubitus interruptus (ci) promotes its proteolysis from the full-length active form to the truncated repressive form, thereby antagonizing the hedgehog (hh) signaling pathway. An inhibitor of PKA was able to block this processing.
70. 70 Jiang J, Struhl G: Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb. Nature 1998, 391:493-496. This article describes a new gene, slimb, that negatively regulates the hh signaling pathway in Drosophila. Slimb encodes an F-box/WD40-repeat protein related to Cdc4p, a protein in budding yeast that targets cell-cycle regulators for degradation by the ubiquitin/proteasome pathway. Slimb mutant cells accumulated high levels of cubitus interruptus (ci) protein, although transcription of the ci gene was unchanged. Ci was found predominantly in its full-length form in slimb mutant cells, suggesting that slimb, similar to PKA, enhances ci proteolysis and thus antagonizes the hedgehog (hh) pathway.
71. 71 Goodrich LV, Milenkovic L, Higgins KM, Scott MP: Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997, 277:1109-1113. This article reports the phenotype of Ptc knockout mice. Mice homozygous for Ptc died during embryogenesis and were found to have open and overgrown neural tubes. Mice heterozygous for the Ptc mutation were larger than normal and had a predisposition to develop medulloblastoma, a tumor seen in patients with Gorlin syndrome. Notably the mice did not develop BCC, suggesting that BCC, and not medulloblastoma, requires somatic inactivation of the second Ptc allele.
72. 72 Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, et al.: Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85:841-851.
73. 73 Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al.: Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996, 272:1668-1671.
74. 74 Xie J, Murone M, Luoh SM, Ryan A, Gu O, Zhang C, et al.: Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 1998, 391:90-92. This article reports the cloning of the human homolog of the smoothened (SMO) gene and its localization to chromosome 7q31-32. Activating somatic missense mutations in SMO were identified in sporadic BCCs from 3 of 47 patients. Mutant SMO, in contrast to the wild-type, was able to transform rat embryo fibroblasts with the adenovirus E1A oncogene. Transgenic mice overexpressing mutant SMO developed skin lesions with microscopic features similar to BCC. These findings provide direct evidence that mutated SMO can function as an oncogene in the development of BCCs.
75. 75 Marigo V, Johnson RL, Vortkamp A, Tabin CJ: Sonic hedgehog differentially regulates expression of GLI and GLI3 during limb development. Dev Biol 1996, 180:273-283.
76. 76 Sasaki H, Hui C, Nakafuku M, Kondoh H: A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. Development 1997, 124:1313-1322.
77. 77 Büscher D, Bosse B, Heymer J, Rüther U: Evidence for genetic control of Sonic hedgehog by Gli3 in mouse limb development. Mech Dev 1997, 62:175-182.
78. 78 Lee J, Platt KA, Censullo P, Ruiz I, Altaba A: Gli1 is a target of Sonic hedgehog that induces ventral neural tube development. Development 1997, 124:2537-2552.
79. 79 Shafei-Benaissa E, Savage JR, Babin P, Larregue M, Papworth D, Tanzer J, et al.: The naevoid basal-cell carcinoma syndrome (Gorlin syndrome) is a chromosomal instability syndrome. Mutat Res 1998, 397:287-292.
80. 80 Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, et al.: The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996, 14:78-81.
81. 81 Wolter M, Reifenberger J, Sommer C, Ruzicka T, Reifenberger G: Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1997, 57:2581-2585.
82. 82 Raffel C, Jenkins RB, Frederick L, Hebrink D, Alderete B, Fults DW, James CD: Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997, 57:842-845.
83. 83 Pietsch T, Waha A, Koch A, Kraus J, Albrecht S, Tonn J, et al.: Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997, 57:2085-2088.
84. 84 Vorechovsky I, Unden AB, Sandstedt B, Toftgard R, Stahle-Backdahl M: Trichoepitheliomas contain somatic mutations in the overexpressed PTCH gene: support for a gatekeeper mechanism in skin tumorigenesis. Cancer Res 1997, 57:4677-4681.
85. 85 Maesawa C, Tamura G, Iwaya T, Ogasawara S, Ishida K, Sato N, et al.: Mutations in the human homologue of the Drosophila patched gene in esophageal squamous cell carcinoma. Genes Chromosomes Cancer 1998, 21:276-279.
86. +/- mice developed medulloblastoma but not rhabdomyosarcoma. Because the knockout mice in these studies were generated via mutations at different exons, the observed phenotypes may be mutation-specific.
87. 87 Fan H, Oro AE, Scott MP, Khavari PA: Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog. Nat Med 1997, 3:788-792. This study builds on the work of Oro et al. (Science 1997, 276:817-821), who demonstrated that transgenic mice overexpressing SHH in the skin developed lesions similar to BCCs. When human keratinocytes overexpressing SHH were grafted to immune-deficient mice, the regenerating skin consistently developed histologic features characteristic of BCC.
88. 88 Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EHJ, Scott MP: Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 1997, 276:817-821.
89. 89 Dahmane N, Lee J, Robins P, Heller P, Ruiz I, Altalba A: Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature 1997, 389:876-881. Ectopic expression of Gli1, a downstream effector of the SHH signaling pathway, in Xenopus embryos resulted in the development of epidermal tumors. Sporadic human BCCs consistently overexpressed Gli1, but not SHH or Gli3. These results suggest that dysregulation of members of the SHH signaling pathway other than PTCH can lead to cancer formation.
90. 90 Reifenberger J, Wolter M, Weber RG, Megahed M, Ruzicka T, Lichter P, Reifenberger G: Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998, 58:1798-1803. Sporadic BCCs and medulloblastomas were investigated for mutation and expression of SMO and PTCH. Missense mutations in SMO were detected in four of 31 BCCs and one of 15 medulloblastomas. Mutations in PTCH were seen in eight BCCs and one medulloblastoma. Two BCCs demonstrated mutations in both genes. Most tumors showed increased expression of SMO, PTCH, and GLI1 transcripts compared with normal tissue. Thus, in addition to PTCH, SMO mutations may contribute to human tumorigenesis.
91. 91 Kinzler KW, Bigner SH, Bigner DD, Trent JM, Law MC, O'Brien SJ, et al.: Identification of an amplified, highly expressed gene in a human glioma. Science 1987, 236:70-73.
92. 92 Hall M, Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. In Advances in Cancer Research, United Kingdom edn. Edited by Vande Woude GF, Klein G. San Diego: Academic Press; 1996:67-108.
93. 93 Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al.: 5′ Cpg island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995, 1:686-692.
94. 94 Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, et al.: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995, 55:4525-4530.
95. 95 Gonzalgo ML, Hayashida T, Bender CM, Pao MM, Tsai YC, Gonzales FA, et al.: The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res 1998, 58:1245-1252.
96. 96 Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995, 83:993-1000.
97. INK4a as a tumor suppressor.
98. 98 Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D: A novel p16INK4A transcript. Cancer Res 1995, 55:2995-2997.
99. 99 Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, et al.: Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 1995, 55:2988-2994.
100. ARF for inactivation.
101. 101 Serrano M, Lee HW, Chin L, Cordon-Cardo C, Beach D, DePinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85:27-37.
102. ARF interferes with MDM2-regulated p53 ubiquitination.
103. ARF actually increased MDM levels.
104. ARF enhances the transcriptional activity of p53.
105. ARF is unnecessary for p53 activation in response to radiation-induced DNA damage, it appears to play a role in the p53-mediated cellular response to oncogenic signals.
106. ARF.
107. 107 Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, et al.: Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995, 10:351-353.
108. 108 Holland EA, Beaton SC, BeckerTM, Grulet OM, Peters BA, Rizos H, et al.: Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 1995, 11:2289-2294.
109. 109 Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, et al.: Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 1995, 4:1845-1852.
110. 110 Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L, Kamb A: Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene 1995, 11:987-991.
111. INK4 gene. Blood 1996, 87:1657-1658.
112. 112 Engelhardt M, Kumar R, Albanell J, Pettengell R, Han W, Moore MA: Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood 1997, 90:182-193.